Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
Kartik Anand, Geetanjali Sahu, Ethan Burns, et al.
ESMO Open (2020) Vol. 5, Iss. 4, pp. e000866-e000866
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

The immunoregulatory landscape of human tuberculosis granulomas
Erin McCaffrey, Michele Donato, Leeat Keren, et al.
Nature Immunology (2022) Vol. 23, Iss. 2, pp. 318-329
Open Access | Times Cited: 187
The role of PD-1 signaling in health and immune-related diseases
Ruyue Chen, Yun Zhu, Yunyan Shen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
Tommaso Morelli, Kohei Fujita, Gil Redelman‐Sidi, et al.
Thorax (2021) Vol. 77, Iss. 3, pp. 304-311
Open Access | Times Cited: 80
Immunotherapies against human bacterial and fungal infectious diseases: A review
Hafsa Qadri, Abdul Haseeb Shah, Mustfa Alkhanani, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 24
Advances in Host–Pathogen Interactions in Tuberculosis: Emerging Strategies for Therapeutic Intervention
Mohammad Javad Nasiri, Vishwanath Venketaraman
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1621-1621
Open Access | Times Cited: 1
The paradox of immune checkpoint inhibition re-activating tuberculosis
Mohamed I. M. Ahmed, Liku B. Tezera, Paul Elkington, et al.
European Respiratory Journal (2022) Vol. 60, Iss. 5, pp. 2102512-2102512
Open Access | Times Cited: 31
Host-Directed Therapies for Tuberculosis
Eui-Kwon Jeong, Hyo-Ji Lee, Yu‐Jin Jung
Pathogens (2022) Vol. 11, Iss. 11, pp. 1291-1291
Open Access | Times Cited: 29
Recent advances in immunotherapies against infectious diseases
Dharanidharan Ramamurthy, Trishana Nundalall, Sanele Cingo, et al.
Immunotherapy Advances (2020) Vol. 1, Iss. 1
Open Access | Times Cited: 49
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?
Akshara Vaddi, Holly J. Hulsebus, Emily L. O’Neill, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 2, pp. 1601-1624
Open Access | Times Cited: 5
Growing from common ground: nontuberculous mycobacteria and bronchiectasis
Eva Van Braeckel, Cédric Bosteels
European Respiratory Review (2024) Vol. 33, Iss. 173, pp. 240058-240058
Open Access | Times Cited: 5
Reinventing the human tuberculosis (TB) granuloma: Learning from the cancer field
Senait Ashenafi, Susanna Brighenti
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
What should intensivists know about immune checkpoint inhibitors and their side effects?
В. Г. Александров, F. Martínez Sagasti, J.A Ruíz Moreno, et al.
Medicina Intensiva (English Edition) (2025), pp. 502135-502135
Closed Access
Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors
Marie Yan, Alejandro Hernandez, Kelvin Chan, et al.
Clinical Infectious Diseases (2025)
Closed Access
Where lung cancer and tuberculosis intersect: recent advances
Chunju Fang, Xuanlu He, Fei Tang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections
Kohei Fujita, Paul Elkington
Respiratory Investigation (2024) Vol. 62, Iss. 3, pp. 339-347
Closed Access | Times Cited: 3
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Eléonora De Martin, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Gut (2024), pp. gutjnl-332125
Closed Access | Times Cited: 3
Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study
Kohei Fujita, Paul Elkington, Gil Redelman‐Sidi, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 11, pp. 2757-2764
Open Access | Times Cited: 11
Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
Shuang Xia, Hui Gong, Yi‐Chang Zhao, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 240-240
Open Access | Times Cited: 11
Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?
Cecilia Azzarà, Andrea Lombardi, Andrea Gramegna, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Lower IL-7 Receptor Expression of Monocytes Impairs Antimycobacterial Effector Functions in Patients with Tuberculosis
Ernest Adankwah, Jean De Dieu Harelimana, Difery Minadzi, et al.
The Journal of Immunology (2021) Vol. 206, Iss. 10, pp. 2430-2440
Open Access | Times Cited: 14
Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review
Andrea Lombardi, Andrea Gramegna, Margherita Ori, et al.
ERJ Open Research (2022) Vol. 8, Iss. 4, pp. 00364-2022
Open Access | Times Cited: 9
Nontuberculous Mycobacterial Pulmonary Disease in the Immunocompromised Host
Cara D. Varley, Amber C Streifel, Amanda M. Bair, et al.
Clinics in Chest Medicine (2023) Vol. 44, Iss. 4, pp. 829-838
Closed Access | Times Cited: 5
The elevated expression of LAG-3 on CD8+T cells correlates with disease severity of pulmonary TB
Jie Chen, Junchi Xu, Yayan Niu, et al.
Microbial Pathogenesis (2023) Vol. 179, pp. 106089-106089
Closed Access | Times Cited: 4
Shift in Tissue-Specific Immune Niches and CD137 Expression in Tuberculoma of Pembrolizumab-Treated Nasopharyngeal Carcinoma Patients
Ngar Woon Kam, Anthony W.I. Lo, Desmond Hung, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 268-268
Open Access | Times Cited: 1
Absence of PD-L1 signaling hinders macrophage defense against Mycobacterium tuberculosis via upregulating STAT3/IL-6 pathway
Peijie Qu, Xinyu Li, Weihuang Liu, et al.
Microbes and Infection (2024) Vol. 26, Iss. 5-6, pp. 105352-105352
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top